MTOR and lung carcinoma: Fibulin2 (FBLN2) is decreased in the lung cancer cell lines, and the overexpression of FBLN2 would inhibit the activation of MAPK/ERK and AKT/mTOR signaling pathways, accompanied by the decreased migration and invasion of cells (64).